Drilldown/Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Anticonvulsant

or Neuroleptic

or [[:Category:Hormone_replacement|Hormone replacement]]

Use the filters below to narrow your results.

Asenapine (1) · Brivaracetam (1) · Cannabidiol (1) · Cenobamate (1) · Chlorpromazine (1) · Clobazam (1) · Droperidol (1) · Eslicarbazepine (1) · Ethosuximide (1) · Felbamate (1) · Fenfluramine (1) · Fluphenazine (1) · Fosphenytoin (1) · Iloperidone (1) · Lacosamide (1) · Levothyroxine (1) · Liothyronine (T3, triiodothyronine sodium) (1) · Loxapine (1) · Lurasidone (1) · Molindone (1) · Paliperidone (1) · Perampanel (1) · Perphenazine (1) · Phenobarbital (1) · Phenytoin (1) · Pimozide (1) · Rufinamide (1) · Stiripentol (1) · Thioridazine (1) · Thiothixene (1) · Thyroid (desiccated) (1) · Tiagabine (1) · Trifluoperazine (1) · Valproic acid (1) · Vigabatrin (1) · Ziprasidone (1) · Zonisamide (1)

Aptiom (1) · Armour Thyroid, NP Thyroid, Nature-Throid, WP Thyroid (1) · Banzel (1) · Briviact (1) · Cerebyx (1) · Cytomel (oral), Triostat (IV) (1) · Depakote (1) · Diacomit (1) · Dilantin (1) · Epidiolex (1) · Fanapt (1) · Felbatol (1) · Fintepla (1) · Fycompa (1) · Gabitril (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Loxitane (1) · Luminal (1) · Mellaril (1) · Moban (1) · Navane (1) · Onfi (1) · Orap (1) · Prolixin (1) · Sabril (1) · Saphris (1) · Stelazine (1) · Synthroid, Levoxyl, Tirosint, Unithroid, Euthyrox (1) · Thorazine (1) · Trilafon (1) · Vimpat (1) · Xcopri (1) · Zarontin (1) · Zonegran (1)

None (1) · AMPA receptor antagonist (1) · Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Phenothiazine D2 antagonist (4) · Prodrug of phenytoin; sodium channel blocker (1) · Serotonin releaser; sigma-1 agonist (1) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · Synthetic T4 (thyroxine); peripherally deiodinated to T3 (triiodothyronine), the active hormone. '"`UNIQ--vote-00000031-QINU`"' Narrow therapeutic index; brand-to-generic switches can shift TSH and require re-titration'"`UNIQ--ref-00000032-QINU`"'. (1) · T-type calcium channel blocker (1) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-00000032-QINU`"' Brand-to-brand and lot-to-lot variability in T3:T4 ratio is greater than with synthetic levothyroxine, which is why endocrine guidelines prefer the synthetic'"`UNIQ--ref-00000033-QINU`"'. (1)

None (34) · '"`UNIQ--vote-00000033-QINU`"', '"`UNIQ--vote-00000034-QINU`"', '"`UNIQ--vote-00000035-QINU`"' (1) · '"`UNIQ--vote-00000034-QINU`"', '"`UNIQ--vote-00000035-QINU`"' (1) · '"`UNIQ--vote-0000149A-QINU`"', '"`UNIQ--vote-0000149B-QINU`"', '"`UNIQ--vote-0000149C-QINU`"' (1)

None (34) · 1.6 mcg/kg/d in young healthy adults; 25-50 mcg/d in elderly or cardiac disease, titrated by TSH at 6-8 weeks (1) · 30 mg PO daily (1/2 grain); titrate by TSH at 6-8 weeks; 60 mg desiccated thyroid is approximately equivalent to 88-100 mcg levothyroxine (1) · Hypothyroidism: 5-25 mcg PO daily (start low, titrate slowly); myxedema coma: 5-20 mcg IV q4-12h with T4 loading (1)

None (34) · 15, 30, 60, 90, 120, 180, 240, 300 mg tablets (1/4 to 5 grains; 1 grain = 60 mg) (1) · 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300 mcg tablets; oral capsule and IV/IM also available (1) · 5, 25, 50 mcg tablets (Cytomel); 10 mcg/mL IV (Triostat) (1)

None (34) · 100 mcg/d typical (1) · No fixed maximum; titrated to TSH target (2)

None (34) · IV (2) · Oral (3)

None (34) · Hours (faster than T4); peak biologic activity 24-48 hours (1) · TSH normalization 4-8 weeks (1) · TSH normalization 4-8 weeks; symptomatic improvement weeks to months (1)

None (34) · 24-72 hours (1) · Steady-state at 4-6 weeks (2)

None (34) · T4 ~7 days; T3 ~1 day'"`UNIQ--ref-00000036-QINU`"' (1) · ~1 day (much shorter than T4's ~7 days)'"`UNIQ--ref-0000149D-QINU`"' (1) · ~7 days (euthyroid); longer in hypothyroidism (~9-10 days), shorter in hyperthyroidism'"`UNIQ--ref-00000036-QINU`"' (1)

None (34) · 40-80% (oral); reduced by food, calcium, iron, PPIs, fiber; take fasting with water'"`UNIQ--ref-00000037-QINU`"' (1) · Variable; reduced by food, calcium, iron, PPIs'"`UNIQ--ref-00000037-QINU`"' (1) · ~95% (oral)'"`UNIQ--ref-0000149E-QINU`"' (1)

None (34) · First-line in pregnancy; dose typically increased 25-30% due to estrogen-driven rise in TBG and fetal demand. Lactation safe at physiologic doses.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Synthetic levothyroxine is the standard-of-care in pregnancy; desiccated thyroid use in pregnancy is not well studied[[[Pharmacopedia:Citation needed|citation needed]]] (1) · T4 (levothyroxine) is the first-line in pregnancy; T3 is rarely needed.[[[Pharmacopedia:Citation needed|citation needed]]] (1)